Human cell-based MIMIC®-PTE modules were used and were either left untreated or were treated with benchmark influenza vaccine (Fluzone®, 2012–13), the TLR7/8 agonist R848, or 6 increasing concentrations of mRNA vaccine (5–50 μg/106 cells). Here, TLR7 is linked to influenza.